Navigation Links
Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
Date:5/26/2008

ients beyond palliative care, and provide specific treatment for Hunter syndrome."

Since its U.S. approval in July 2006, ELAPRASE has been approved for marketing and commercial distribution in several countries around the world, most recently in Mexico and Russia.

[1] Caggeso, Mike. "Outlook 2008: The Latin American Economy is 'Muy Caliente'", Money Morning. January 8, 2008 <http://www.moneymorning.com/2008/01/08/outlook-2008-the-latin-american-eco no my-is-muy-caliente%C2%A0/> (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

Notes to editors

About ELAPRASE(R)

ELAPRASE is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line. ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II.) ELAPRASE has been shown to improve walking capacity in these patients.

Safety Considerations

Some patients in the clinical trials experienced life-threatening immediate allergic reactions to ELAPRASE (idursulfase) infusion. Patients who have experienced severe allergic reactions may experience another allergic reaction approximately 24 hours after the initial reaction and may require prolonged observation. Patients with compromised respiratory function or acute respiratory disease may have a higher risk of life-threatening reactions to ELAPRASE infusion and require additional monitoring.

Life-threatening allergic reactions have been seen in some patients during ELAPRASE infusions. Reactions included difficulty breathing, lack of oxygen, seizure or loss of consciousness, hives, and/or swelling of the throat or tongue. Patients received an antihistamine to reverse the allergic reaction or corticosteroid to decre
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
2. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
3. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
4. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
5. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
6. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
7. BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials
8. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
11. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... your doctor know what you,re smoking?  Chances are, probably not.  ... over 112,000 currently registered patients under Colorado,s ... 20,300+ active physicians listed with the Colorado Dept of Regulatory ... a poll in February 2014 showed 51% of ... "With marijuana legalization underway, every doctor needs a ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... in Patients Following Bunionectomy, TAMPA, Fla., May ... several days following removal of a,bunion, one of ... tapentadol provided significant relief for patients who had ... with tapentadol,also resulted in patients reporting fewer gastrointestinal ...
... X-ray ... Data -, ... two-year Phase III study showing that ACTEMRA(TM),(tocilizumab) can significantly inhibit progression of ... of,effectiveness of an RA treatment. The study also demonstrated that ACTEMRA,reduces disease ...
Cached Medicine Technology:New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 3New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 4New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 5New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5
(Date:8/30/2014)... Rapids, MI (PRWEB) August 30, 2014 ... residents, Forefront Dermatology is expanding with the addition of ... Dr. David Hammond who has provided leading-edge skin care ... with Forefront Dermatology. , “As a doctor, my ... they deserve. Through partnering with Forefront Dermatology, I’m better ...
(Date:8/30/2014)... Colorado Springs, CO (PRWEB) August 30, 2014 ... valuable, and increasingly difficult to get. Snoring and sleep apnea ... breathing stops) rob people and their bed partners of the ... Up to 45% of the population snores and 20 million ... these, only 10% have been diagnosed and treated; and of ...
(Date:8/30/2014)... "My wife suffered neck, back and spine ... one of two inventors from Bethel, Alaska. "The whiplash ... neck area. She tried other pillows to little avail. ... in comfort and providing extra sleep." , They created ... the head, neck and back comfortably. This enables the ...
(Date:8/30/2014)... 2014 Market Research Report on ... a professional and in-depth market survey on Global ... reviews the basic information of Lab Oven including ... then explores global and China’s top manufacturers of ... value, and market share etc. , The report ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 Serving ... company in India, Profit By Outsourcing is now ... Development services. The company gives emphasize on putting forward ... complete product to clients. Their dedicated team of professionals ... ground-breaking results. They can handle even the critical issues ...
Breaking Medicine News(10 mins):Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2
... the cultivation of grains was a boon to humankind, giving ... term and would sustain them through drought and famine. Grains, ... , A new research project co-led by Mary Lou Guerinot, ... is aimed at making rice which supplies an estimated ...
... that in cell cultures, the stress hormone norepinephrine appears ... cells to grow and spread. , The finding, ... progression and spread of some cancers enough so that ... work. , The study also showed that stress ...
... Inc. (OTC,Bulletin Board: BMRX) announced today that Wendy ... Ms. Borow-Johnson just completed serving as the President ... of The Networks Group of,Turner Media Group, Inc. ... and Fashion, Men,s Channel, Mall TV, Resorts and,Residence ...
... CITY, Calif., Nov. 19 People grow a ... no different. SleepQuest, the leader in,at-home diagnostic sleep ... pains which accompany rapid growth by moving into ... Magazine,s 5000 Fastest Growing Private,Companies in America, SleepQuest ...
... levels of work-related stress, according to a University of ... workers. , The study, presented in San Francisco at ... is based on 2006 data from 1,544 participants in ... U-M Institute for Social Research (ISR) and funded by ...
... Calif., Nov. 19 ,Natrol, Inc, (Nasdaq: NTOL ... nutritional products, and Gener8Xion Entertainment, Inc.,(OTC Bulletin Board: ... a letter of intent for a strategic,alliance to ... intends to,exclusively license the "Living Pure" brand to ...
Cached Medicine News:Health News:'Biofortifying' one of the world's primary foods 2Health News:Stress hormone may hasten the progression of certain blood cancers 2Health News:Stress hormone may hasten the progression of certain blood cancers 3Health News:Wendy Borow-Johnson to Join bioMETRX Board of Directors 2Health News:Wendy Borow-Johnson to Join bioMETRX Board of Directors 3Health News:SleepQuest Continues Growth, Moves Headquarters 2Health News:Older workers stress less, U-M study suggests 2Health News:Older workers stress less, U-M study suggests 3Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 2Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 3Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 4
... The Stockert 70 RF ... the EP lab every day, ... the Stockert 70 and the ... NAVI-STAR Diagnostic/Temperature Ablation Catheter provide ...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... The Identity pacemaker family, ... dual-chamber pacemaker, provides clinicians with ... available, including the revolutionary AF ... only U.S. commercially approved algorithm ...
... Frontier II device is designed ... moderate to severe heart failure ... in patients who are symptomatic ... and who have prolonged QRS ...
Medicine Products: